BioSpace News Archive

Business

Rho Announces Grand Opening of New Headquarters Building in Research Triangle Park

Rho, a full-service contract research organization (CRO) focused on bringing new products to market through a full range of product development services, announced today the official opening of its new 159,000-square-foot headquarters building in Research Triangle Park (RTP), North Carolina.

May 1, 2019
·
2 min read
Biotech Beach

CORRECTING and REPLACING Vivera Pharmaceuticals Licenses TABMELT®, a Sublingual Pharmaceutical Drug-Delivery System for Cannabidiol (CBD)

Company to focus on benefits of CBD for non-addictive pain management and opioid, alcohol addiction recovery

May 1, 2019
·
5 min read
Deals

Bristol-Myers Squibb Company Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Celgene Corporation Notes

Bristol-Myers Squibb Company announced that the requisite number of consents have been received to adopt proposed amendments with respect to all outstanding notes of Celgene Corporation.

May 1, 2019
·
9 min read
Business

ICON Reports First Quarter 2019 Results

ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2019.

May 1, 2019
·
6 min read
Manufacturing growth sees surging demand at CPhI South East Asia

SE Asian demand for manufacturing is being driven by recent regulatory changes and increased generics from Indonesia, Malaysia and the Philippines.

May 1, 2019
·
4 min read
Par Pharmaceutical, Inc. Issues Voluntary Nationwide Recall of One Lot of Mycophenolate Mofetil for Injection, USP Due to the Presence of a Glass Fragment Observed in One Vial of Reconstituted Product

One vial of product was observed containing a glass fragment after reconstitution.

May 1, 2019
·
5 min read
FDA

First FDA-approved vaccine for the prevention of dengue disease in endemic regions

The U.S. Food and Drug Administration announced the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes in people ages 9 through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.

May 1, 2019
·
5 min read
FDA

FDA approves Dengvaxia® for the prevention of dengue in individuals ages 9 through 16 living in U.S. endemic areas

The U.S. Food and Drug Administration approved Dengvaxia® for the prevention of dengue disease caused by serotypes 1 – 4 of the virus in individuals 9 through 16 years of age living in endemic areas of the U.S. with a laboratory-documented prior infection.

May 1, 2019
·
5 min read
Biotech Beach

AVITA Medical to Present at RBC Capital Markets 2019 Healthcare Conference

AVITA Medical, a global regenerative medicine company, announced that management will present at the RBC Capital Markets 2019 Healthcare Conference in New York.

May 1, 2019
·
4 min read